Pediatric Bladder Tumors: A Ten-Year Retrospective Analysis.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
11 2022
Historique:
received: 06 04 2022
revised: 27 07 2022
accepted: 01 08 2022
pubmed: 16 8 2022
medline: 16 11 2022
entrez: 15 8 2022
Statut: ppublish

Résumé

To present our experience in a single pediatric urology practice over a 10-year period with bladder tumors in the pediatric population in an effort to add to the relatively small amount of existing data. We hope to expand the community's knowledge of presentations, management and natural history of pediatric bladder tumors. We retrospectively queried our electronic medical records for International Classification of Diseases, Tenth Revision (ICD-10) and Current Procedural Terminology (CPT) codes relevant for bladder tumors. Patients with underlying bladder pathology, such as neurogenic bladder, history of bladder exstrophy, and history of bladder augmentation, were excluded. We identified 30 patients with bladder tumors from 2011 to 2021. There were 21 males and 9 females. Age at diagnosis ranged from 16 months to 19 years. Tumors identified were: 11 of various inflammatory subtypes; 4 papillomas; 4 rhabdomyosarcomas; 3 papillary urothelial neoplasms of low malignant potential and 8 of other types. Treatment included transurethral resection of bladder tumor, chemoradiation and laparoscopic partial cystectomy. Twenty nine patients had disease limited to the bladder and 1 had disease outside the bladder. Follow-up ranged from 2 weeks to 13 years (median 19 months). All patients had no evidence of disease at most recent follow-up. Pediatric bladder tumors range from aggressive rhabdomyosarcomas to more benign urothelial lesions. Fortunately, the latter type of tumor is the more prevalent lesion. Knowledge of the treatment options and natural history of these tumors will hopefully be of benefit to clinicians and parents alike.

Identifiants

pubmed: 35970356
pii: S0090-4295(22)00696-3
doi: 10.1016/j.urology.2022.08.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

185-190

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Andrew D Shumaker (AD)

Pediatric Urology Associates, P.C. Tarrytown, NY. Electronic address: AndrewDavidShumaker@gmail.com.

Miriam Harel (M)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Jordan Gitlin (J)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Steven C Friedman (SC)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Lori Dyer (L)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Jaime Freyle (J)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Paul F Zelkovic (PF)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Mark Horowitz (M)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Ronnie G Fine (RG)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Richard N Schlussel (RN)

Pediatric Urology Associates, P.C. Tarrytown, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH